TATVA Stock Overview
Engages in manufacture and sale of specialty chemicals in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Tatva Chintan Pharma Chem Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹843.15 |
| 52 Week High | ₹1,650.85 |
| 52 Week Low | ₹788.50 |
| Beta | 0.063 |
| 1 Month Change | 1.37% |
| 3 Month Change | -14.59% |
| 1 Year Change | -46.22% |
| 3 Year Change | -66.28% |
| 5 Year Change | n/a |
| Change since IPO | -63.53% |
Recent News & Updates
Tatva Chintan Pharma Chem Limited's (NSE:TATVA) Price In Tune With Revenues
Sep 26
Tatva Chintan Pharma Chem (NSE:TATVA) Has Affirmed Its Dividend Of ₹2.00
Aug 29Recent updates
Tatva Chintan Pharma Chem Limited's (NSE:TATVA) Price In Tune With Revenues
Sep 26Tatva Chintan Pharma Chem (NSE:TATVA) Has Affirmed Its Dividend Of ₹2.00
Aug 29Earnings Report: Tatva Chintan Pharma Chem Limited Missed Revenue Estimates By 33%
Jul 27Weak Statutory Earnings May Not Tell The Whole Story For Tatva Chintan Pharma Chem (NSE:TATVA)
May 11Tatva Chintan Pharma Chem Limited's (NSE:TATVA) Share Price Matching Investor Opinion
Apr 04These Analysts Just Made A Notable Downgrade To Their Tatva Chintan Pharma Chem Limited (NSE:TATVA) EPS Forecasts
Jan 26Tatva Chintan Pharma Chem Limited (NSE:TATVA) Analysts Are Reducing Their Forecasts For This Year
May 10Tatva Chintan Pharma Chem Limited Just Missed Revenue By 15%: Here's What Analysts Think Will Happen Next
Jul 28Getting In Cheap On Tatva Chintan Pharma Chem Limited (NSE:TATVA) Is Unlikely
Jun 17Investors Shouldn't Be Too Comfortable With Tatva Chintan Pharma Chem's (NSE:TATVA) Robust Earnings
May 03Are Investors Undervaluing Tatva Chintan Pharma Chem Limited (NSE:TATVA) By 45%?
Dec 06Shareholder Returns
| TATVA | IN Chemicals | IN Market | |
|---|---|---|---|
| 7D | -4.9% | -2.5% | -2.1% |
| 1Y | -46.2% | 8.5% | 22.5% |
Return vs Industry: TATVA underperformed the Indian Chemicals industry which returned 8.5% over the past year.
Return vs Market: TATVA underperformed the Indian Market which returned 22.5% over the past year.
Price Volatility
| TATVA volatility | |
|---|---|
| TATVA Average Weekly Movement | 5.9% |
| Chemicals Industry Average Movement | 5.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: TATVA has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: TATVA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 689 | Chintan Shah | www.tatvachintan.com |
Tatva Chintan Pharma Chem Limited engages in manufacture and sale of specialty chemicals in India and internationally. It offers a portfolio of structure directing agents for zeolites synthesis; phase transfer catalysts; electrolyte salts for super capacitor and zinc ion batteries; and pharmaceutical and agrochemical products, and other specialty chemicals in the form of intermediates, disinfectants, catalysts, and solvents. The company serves automotive, refinery, pharmaceutical, agro-chemicals, paints and coatings, dyes and pigments, personal care, and flavor and fragrances industries.
Tatva Chintan Pharma Chem Limited Fundamentals Summary
| TATVA fundamental statistics | |
|---|---|
| Market cap | ₹19.72b |
| Earnings (TTM) | ₹176.14m |
| Revenue (TTM) | ₹3.71b |
112.0x
P/E Ratio5.3x
P/S RatioIs TATVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TATVA income statement (TTM) | |
|---|---|
| Revenue | ₹3.71b |
| Cost of Revenue | ₹1.87b |
| Gross Profit | ₹1.84b |
| Other Expenses | ₹1.66b |
| Earnings | ₹176.14m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.53 |
| Gross Margin | 49.56% |
| Net Profit Margin | 4.74% |
| Debt/Equity Ratio | 2.1% |
How did TATVA perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield15%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 17:57 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tatva Chintan Pharma Chem Limited is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sanjesh Jain | ICICI Securities Ltd. |
| Anshuman Gupta | Investec Bank plc (UK) |
| Krishanchandra Parwani | JM Financial Institutional Securities Limited |